anti-CD40-7409

anti-CD40-7409 is a monoclonal antibody targeting the CD40 receptor, currently in Phase I clinical development for the treatment of cancer. Developed by Protheragen, this therapeutic candidate acts as an agonist of CD40 (tumor necrosis factor receptor superfamily member 5), a cell surface receptor primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. By binding to CD40, the antibody mimics the signaling of CD40 ligand (CD154), triggering APC maturation, upregulation of co-stimulatory molecules, and enhanced cytokine production. This process facilitates the activation of tumor-specific T cells, thereby promoting a robust anti-tumor immune response. The asset is currently listed as an available project for licensing and collaborative development.